Levodopa continues to be the most efficacious dopaminergic agent in the treatment of parkinsonian motor symptoms. Its long term administration, however, combined with the progressive loss of cells in advanced disease, is associated with the wearing 'off' episodes and dyskinesia. COMT inhibition through Tolcapone and Entacapone may alleviate these motor complications.
|Original language||English (US)|
|Title of host publication||Encyclopedia of Movement Disorders|
|Number of pages||4|
|State||Published - Jan 1 2010|
- Parkinson's disease
ASJC Scopus subject areas